• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ:BIIB)

211.38 -1.12 (-0.53%)
Streaming Delayed Price Updated: 2:22 PM EDT, Sep 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 318,145
Open 210.50
Bid (Size) 211.22 (100)
Ask (Size) 211.74 (200)
Prev. Close 212.50
Today's Range 209.00 - 213.48
52wk Range 135.39 - 225.80
Shares Outstanding 146,800,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest
September 08, 2026
Wrapping up Q2 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including United Therapeutics (NASDAQ:UTHR) and its peers. Ove... 
Via StockStory
Topics Artificial Intelligence
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
Via Investor Brand Network

Performance

YTD
+18.9%
+18.9%
1 Month
+2.0%
+2.0%
3 Month
+6.2%
+6.2%
6 Month
+12.2%
+12.2%
1 Year
+49.5%
+49.5%

More News

Read More
InvestorNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Gains Editorial Spotlight Following FDA Clearance for Lucid-MS Phase 2 Trial
September 08, 2026
Via Investor Brand Network
Biogen (NASDAQ:BIIB) Shows Strong Technical Breakout Setup With Perfect Trend Rating ↗
August 17, 2026
Via Chartmill
News headline image
A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach
September 08, 2026
From BioMedWire
Via GlobeNewswire
News headline image
Therapeutics Stocks Q2 Recap: Benchmarking Myriad Genetics (NASDAQ:MYGN)
September 07, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 03, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 03, 2026
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 01, 2026
From Stoke Therapeutics, Inc.
Via Business Wire
News headline image
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
September 01, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Highlights: Moderna (NASDAQ:MRNA) Vs The Rest Of The Therapeutics Stocks
August 27, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Unpacking Q2 Earnings: Novavax (NASDAQ:NVAX) In The Context Of Other Therapeutics Stocks
August 25, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
August 25, 2026
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Therapeutics Stocks Q2 Results: Benchmarking BioMarin Pharmaceutical (NASDAQ:BMRN)
August 19, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
Biogen (BIIB) Q2 2026 Earnings Call Transcript ↗
August 07, 2026
Via The Motley Fool
Topics Earnings
News headline image
Biogen Completes Acquisition of RayThera Inc.
August 06, 2026
From Biogen Inc.
Via GlobeNewswire
News headline image
The 5 Most Interesting Analyst Questions From Biogen’s Q2 Earnings Call
August 05, 2026
Via StockStory
Topics Earnings
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
August 03, 2026
Via The Motley Fool
News headline image
BIIB Q2 Deep Dive: Portfolio Expansion and Pipeline Readouts Drive Upbeat Outlook
July 30, 2026
Via StockStory
News headline image
Why Biogen Stock Topped the Market Today ↗
July 29, 2026
Via The Motley Fool
News headline image
Biogen Q2 Earnings Call Highlights ↗
July 29, 2026
Via MarketBeat
Topics Earnings
News headline image
Biogen (NASDAQ:BIIB) Reports Upbeat Q2 CY2026
July 29, 2026
Via StockStory
News headline image
Biogen (BIIB) Reports Q2: Everything You Need To Know Ahead Of Earnings
July 27, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
3 Profitable Stocks We Steer Clear Of
July 21, 2026
Via StockStory

Frequently Asked Questions

Is Biogen Idec publicly traded?
Yes, Biogen Idec is publicly traded.
What exchange does Biogen Idec trade on?
Biogen Idec trades on the Nasdaq Stock Market
What is the ticker symbol for Biogen Idec?
The ticker symbol for Biogen Idec is BIIB on the Nasdaq Stock Market
What is the current price of Biogen Idec?
The current price of Biogen Idec is 211.38
When was Biogen Idec last traded?
The last trade of Biogen Idec was at 09/09/26 02:22 PM ET
What is the market capitalization of Biogen Idec?
The market capitalization of Biogen Idec is 31.03B
How many shares of Biogen Idec are outstanding?
Biogen Idec has 31B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap